About the Symposium and Dr. Comis

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) hosts the **Robert L. Comis, MD Translational Science Symposium** at Group meetings. This plenary symposium is open to all attendees. The overall goal of the event is to seed ideas for ECOG-ACRIN's various scientific committees to explore within and across its scientific programs. Each symposium offers a focused examination of a particular field of scientific opportunity.

Robert L. Comis, MD was an innovative researcher who recognized the potential for translational research to advance cancer prevention, detection, and treatment. Some of the most important national late-stage clinical trials were conducted under his leadership of the Group (1995-2017). He spearheaded scores of scientific discoveries that changed clinical practice across multiple types of cancer. ECOG-ACRIN is pleased to honor him through this event.

Dr. Comis' interest in oncology began early in his career at the National Cancer Institute (NCI) when he was sent to Uganda to provide chemotherapy to children suffering from Burkitt's lymphoma. After a fellowship at the Dana-Farber Cancer Institute, he embarked on a career focused on lung cancer and developmental therapeutics. He built centers of excellence in the research and treatment of cancer, first in Syracuse then at Fox Chase Cancer Center and Thomas Jefferson University in Philadelphia.

Dr. Comis envisioned the merger that resulted in the ECOG-ACRIN Cancer Research Group in 2012. He led the effort to coalesce the new group into what it is today: a scientific community of researchers in cancer biology, immunology, therapeutics, molecular and imaging diagnostics, and comparative effectiveness and patient-reported outcomes research, as well as bioinformatics and biostatistical expertise.

A giant in the field, he was a tireless advocate for patient access to trials and a champion for underserved populations. As a mentor, he helped launch many careers by fostering scientific inquiry among early-career oncologists. Many of his trainees are the new leaders in the field, and will carry on his legacy.

Robert L. Comis, MD Translational Science Symposium

Big Data – Real World Data (RWD)

Wednesday, May 4, 2022
4:00 – 6:00 PM
Chicago Marriott Downtown Magnificent Mile
Salon A – D – 5th Floor
Chicago, Illinois

ECOG-ACRIN
cancer research group

Agenda

4:00 PM	Welcome	Peter J. O'Dwyer, MD and Mitchell D. Schnall, MD, PhD *ECOG-ACRIN and University of Pennsylvania*
	Speakers and Panel Introduction	Clifford S. Goodman, PhD *Lewin Group*
4:05 PM	Real World Evidence Review	Al B. Benson III, MD *ECOG-ACRIN and Northwestern University*
	DATA	
4:15 PM	Building Longitudinal Registries of the Future	Nathan C. Nussbaum, MD *Verily Life Sciences*
	REGULATORY/METHODOLOGY	
4:25 PM	Clinical Evidence Generation: An OCE Perspective	Donna R. Rivera, PharmD, MS *Food and Drug Administration*
	PAYER	
4:35 PM	Using Real World Evidence to Make Decisions: A Health Plan Perspective	Jennifer L. Malin, MD, PhD *Optum Health Solutions*
	PHARMA	
4:45 PM	Real World Data in Drug Development and Approval: How Useful Is It and How Useful Can It Be?	Mace L. Rothenberg, MD *Independent Board Member, Tango Therapeutics, Surrozen and Aulos Bioscience*
4:55 PM	Panel Discussion	Otis W. Brawley, MD *Johns Hopkins University* Joel Saltz, MD, PhD *Stony Brook University*
6:00 PM	Adjourn	

Speakers

Joel Saltz, MD, PhD

Stony Brook University

Dr. Saltz is the Cherith Professor and Founding Chair, Department of Biomedical Informatics, and the vice chair for laboratory initiatives and digital medicine in the Department of Pathology at Stony Brook University. He also serves as vice president for clinical informatics, Stony Brook Medicine, and associate director, Stony Brook Cancer Center. Dr. Saltz is a pioneer in developing digital pathology tools, methods, and algorithms, with the ultimate goal of extracting and leveraging digitalized pathology information to better predict cancer outcome and to steer cancer therapy. He is also an expert in high end computing and has developed a variety of highly cited systems software methods. His research in pathology spans twenty years and consists of closely coordinated efforts in image analysis, machine learning, database design, and high end computing.

Mitchell D. Schnall, MD, PhD

University of Pennsylvania

Dr. Schnall is the co-chair of the ECOG-ACRIN Cancer Research Group, a position he has held since the founding of the Group in 2012. Dr. Schnall co-leads the organization's governance and is a member of several scientific committees. He currently oversees the Tomosynthesis Mammographic Imaging Screening Trial (TMIST) and has a significant influence on emerging imaging technologies, including those in optical imaging. He is chairman of the Department of Radiology and the Eugene P. Pendergrass Professor of Radiology at the Perelman School of Medicine, University of Pennsylvania in Philadelphia. He is a physician at Penn Medicine within its Abdominal Imaging Services program. Dr. Schnall is an international leader in translational biomedical and imaging research, working throughout his career across the interface between basic imaging science and clinical medicine to ensure effective integration of radiology research with other medical disciplines.

Speakers

Donna R. Rivera, PharmD, MS

Food and Drug Administration

Dr. Rivera is the associate director for pharmacoepidemiology in the Oncology Center of Excellence (OCE) at the FDA. She leads the Oncology Real World Evidence (RWE) Program, focused on the use of Real World Data (RWD) and RWE for regulatory purposes, and management of the RWD research portfolio strategy and development of regulatory policy to support the OCE mission. Dr. Rivera has interests in the use of RWD to advance health equity, observational study designs and methodological approaches, and appropriate uses of RWD for drug development to increase access of effective therapies to patients. She is a Scientific Executive Committee member for the COVID-19 and Cancer Consortium and leads Project Post COVIDity, a collaborative RWD effort to assess longitudinal sequalae, outcomes, safety, vaccination, and immunity.

Mace L. Rothenberg, MD

Independent Board Member,
Tango Therapeutics, Surrozen, and Aulos Bioscience

Dr. Rothenberg is a medical oncologist with more than 30 years of experience spanning government, academia, and industry. He served as chief medical officer of Pfizer from 2019 to 2021. During this time, the company initiated, completed, and obtained emergency use authorization for its COVID-19 vaccine. Prior to that role, he led Clinical Development for Oncology at Pfizer from 2008 to 2018. Over that period, his organization developed and obtained regulatory approval for 11 new cancer medicines. Prior to joining Pfizer, Dr. Rothenberg was professor of medicine at Vanderbilt University and Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center. He was also associate professor of medicine at the University of Texas Health Science Center at San Antonio and executive officer of SWOG. Dr. Rothenberg is board-certified in Internal Medicine and Medical Oncology and is a Fellow of the American College of Physicians and the American Society of Clinical Oncology.

Speakers

Al B. Benson III, MD

Northwestern University and the
Robert H. Lurie Comprehensive Cancer Center

Dr. Benson is a professor of medicine in the Division of Hematology/Oncology at Northwestern University's Feinberg School of Medicine. He is also the associate director for cooperative groups at the Robert H. Lurie Comprehensive Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, at Northwestern University. In addition, he is an attending physician at Northwestern Memorial Hospital, a staff physician at Jesse Brown VA Medical Center, and a consultant to the Shirley Ryan AbilityLab (Rehabilitation Institute of Chicago). His positions within ECOG-ACRIN include vice chair, member of the Executive Committee, deputy chair for policy and implementation, co-chair of the Cancer Care Delivery Research Committee, chair of the Data Monitoring Therapeutic Subcommittee, member of the Principal Investigator Committee and past chair of the GI Committee.

Otis W. Brawley, MD

Johns Hopkins University and the
Sidney Kimmel Comprehensive Cancer Center

Dr. Brawley is the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. He is an authority on cancer screening and prevention and leads a broad interdisciplinary research effort focused on cancer health disparities at the Johns Hopkins School of Medicine, the Bloomberg School of Public Health, and the Sidney Kimmel Comprehensive Cancer Center. Prior to coming to Hopkins, he served as the chief medical and scientific officer of the American Cancer Society for more than a decade. Brawley is a Fellow of the Royal College of Physicians (London), a Fellow of the American Society of Clinical Oncology, a Fellow of the American Association for Cancer Research Academy, a Fellow of the American College of Epidemiology and one of the few physicians to be named a Master of the American College of Physicians. He is an elected member of the National Academy of Medicine.

Speakers

Clifford S. Goodman, PhD

Lewin Group

Dr. Goodman is a senior vice president at The Lewin Group, a health care policy consulting firm based in Falls Church, Virginia. He has more than 30 years of experience in such areas as health technology assessment, evidence-based health care, clinical practice guidelines, and studies pertaining to health care innovation, regulation, and payment. He directs studies and projects for an international range of government agencies; life sciences companies; health care provider institutions; and professional, industry, and patient advocacy groups. Dr. Goodman is an internationally recognized health policy issues moderator and facilitator of symposia, expert panels, and advisory boards. Dr. Goodman served as chair of the Medicare Evidence Development & Coverage Advisory Committee (2009-12) for the Centers for Medicare and Medicaid Services. He also served as president of Health Technology Assessment International (2011-13).

Jennifer L. Malin, MD, PhD

Optum Health Solutions

Dr. Malin is the chief medical officer of Optum Health Solutions. In this role, she provides the leadership for clinical programs that deliver improved health outcomes and value, focused on individuals with complex specialty conditions and rare diseases. After graduating from Harvard University, Dr. Malin received her medical degree and doctorate in public health from UCLA. She is board certified in internal medicine and medical oncology. She is the author of more than 100 peer-reviewed articles and is widely recognized for her research on the quality of care. She was a clinical professor of medicine at the UCLA David Geffen School of Medicine and has served on a number of advisory boards and national committees, including National Quality Forum's Cancer Steering Committee, the Health Care Payment Learning and Action Network Clinical Episodes Payment Workgroup, and the National Academy of Medicine Roundtable on Quality Care for People with Serious Illness.

Speakers



Nathan C. Nussbaum, MD

Verily Life Sciences

Dr. Nussbaum leads the clinical data innovation on the Clinical Studies Platforms team at Verily, where he focuses on the creation of longitudinal datasets to power evidence generation. Prior to Verily, he served as senior medical director at Flatiron Health, where he focused on conducting outcomes research and assembling oncology real-world datasets. During his time at Flatiron, Dr. Nussbaum maintained a clinical practice at Bellevue Hospital's Cancer Center and was a clinical instructor at New York University School of Medicine. He is board certified in internal medicine and medical oncology. Dr. Nussbaum received his MD from Johns Hopkins University and trained in internal medicine at the Hospital of the University of Pennsylvania. He then completed his medical oncology fellowship at Duke University, where he was also a fellow at the Duke Clinical Research Institute. He has a Bachelor's degree from Yale University.

Peter J. O'Dwyer, MD

University of Pennsylvania and the Abramson Cancer Center

Dr. O'Dwyer is the co-chair of the ECOG-ACRIN Cancer Research Group since May 2017. A medical oncologist with expertise in gastrointestinal and pancreatic cancers, Dr. O'Dwyer is a physician at Penn Medicine and a professor of medicine at the University of Pennsylvania since 1999. Within ECOG-ACRIN, he co-chairs the landmark NCI-MATCH precision medicine cancer trial. He is the CEO and chair of the PrECOG, LLC Board of Managers and president of the ECOG Research and Education Foundation. Dr. O'Dwyer received his medical degree at the University of Dublin, Trinity College, and completed his residency at the Hammersmith Hospital in London. After a fellowship at the Baltimore Cancer Research Center, he became a senior investigator in the Division of Cancer Treatment at the National Cancer Institute. Dr. O'Dwyer previously led the Developmental Therapeutics Programs at Fox Chase Cancer Center and the University of Pennsylvania.